Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries has reported results for fourth quarter (Q4) and year ended March 31, 2025.

The company has reported over 2-fold jump in its net profit at Rs 2000.46 crore for the quarter under review as compared to Rs 867.60 crore for the same quarter in the previous year. The total income of the company increased by 27.09% at Rs 7317.74 crore for Q4FY25 as compared to Rs 5758.02 crore for the corresponding quarter previous year.

On consolidated basis, the company has reported 18.99% fall in its net profit at Rs 2153.93 crore for fourth quarter ended March 31, 2025 as compared to Rs 2658.74 crore for the same quarter in the previous year. However, the total income of the company increased by 7.81% at Rs 13571.71 crore for Q4FY25 as compared to Rs 12588.84 crore for the corresponding quarter previous year.

For the year ended March 31, 2025, the company has reported 49.84% rise in its net profit at Rs 4282.62 crore as compared to Rs 2858.18 crore for the previous year. The total income of the company increased by 12.69% at Rs 23372.76 crore for year under review as compared to Rs 20740.93 crore for year ended March 31, 2024.

For the year ended March 31, 2025, on the consolidated basis, the company has reported 14.10% rise in its net profit at Rs 10964.75 crore as compared to Rs 9610.03 crore for the previous year. The total income of the company increased by 9.41% at Rs 54543.48 crore for year under review as compared to Rs 49851.04 crore for year ended March 31, 2024.